Conversion calendar in hand: management narrates the coming year as dated deliveries of business already secured
The model's full reasoning — Q4 2021 call → NOThe question asks whether management lays out a timetable of specific conversions — identified pieces of business already secured or in motion, each attached to an at-least-approximate time frame — so the forward story reads as a schedule of things turning on. Let me review the transcript for what management says about the forward quarters. Key forward-looking statements: - Ross: "full year revenue for fiscal 2022 to be in the range of $51.5 million to $54 million, implying growth of 27% to 33%" - Ross: "we would anticipate our results to be slightly more second half-weighted versus 2021, given the timing of several key product launches as well as the anticipated ramp of key new business wins." What are the "key product launches" and "key new business wins"? Let me look for specifics. - HRD solution: launched, with SOFIVA GENOMICS onboarding, AstraZeneca partnership announced. But no specific timing of revenue contribution. - CarePath: "we expect to unveil several exciting new products later this year, one being CarePath" — but CarePath commercialization is "not before end of 2023" per Jurgi's answer to Tejas: "you shouldn't expect the CarePath being commercialized before end of 2023." - DEEP-Lung-IV study: "we will provide an update on preliminary findings at ASCO this year" — but this is a study, not a secured revenue item. - GE partnership: "working together on a new statement of work to begin developing the software infrastructure" — still in development, not secured revenue. - Ambry Genetics: "signed a letter of intent" — LOI, not a binding contract, and no timing given. - New customers in Japan, South Korea, Singapore, Hong Kong — signed, but no timing of revenue contribution. - "expecting several signed agreements with Tier 1 institutions in the coming months" — these are expected, not yet signed. So what's actually secured and on a timetable? - The guidance itself is a range, but the drivers are described as "timing of several key product launches as well as the anticipated ramp of key new business wins" — these are anticipated, not yet secured with specific timing. - The HRD solution is launched and has customers onboarding (SOFIVA), but no specific revenue timing. - The AstraZeneca partnership is announced but no timing of contribution. - CarePath is not commercialized until end of 2023.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ESEA | Euroseas Ltd. | Q4 2022 | 2023-02-15 | C+ |
| SOL | ReneSola Ltd | Q3 2022 | 2022-12-01 | C+ |
| FLL | Full House Resorts, Inc. | Q3 2022 | 2022-11-07 | B |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| ESE | ESCO Technologies Inc. | Q2 2016 | 2016-05-03 | A |
CPK · Q3 2017 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured business and approximate time frames.
SOL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.
FLL · Q3 2022 → YESThe question is about whether management lays out a timetable of specific conversions for the next four or so quarters, with already secured items and approximate time frames.